ijms-logo

Journal Browser

Journal Browser

The Nanoparticle Revolution: Cross Disciplinary Approaches to Disease Study and Treatment Design

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1390

Special Issue Editors


E-Mail Website
Guest Editor
Italian National Research Council-Institute of Biochemistry and Cell Biology, Monterotondo, Italy
Interests: cardiovascular science; non coding RNA; intercellular comunication; cardiac fibroblasts; cardiac organoids

E-Mail Website
Guest Editor
Institute of Crystallography, National Council of Research (IBBC-CNR), 00015 Rome, Italy
Interests: nanomaterials; nanoparticle immobilization; nanoparticle functionalization; biosensors; colloidal synthesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanoparticles are gaining increasing attention in the medical science field. Their reduced dimensions, as well as the high degree of freedom in nanoparticle design, synthesis and functionalization, has allowed their use in multiple investigations on disease. Suitably engineered nanoparticles can be used for targeted drug delivery, as therapeutic agents, for cell tracing, and in theranostic applications.

The success in using nanoparticles for disease study and treatment design relies on the cross disciplinary approaches merging chemistry, material science, biophysics, and biomedical sciences.

To date, nanoparticle-centered projects are focused mainly on dissecting and treating cancer; however, the wide application range of functional nanoparticles makes them appealing in other pathological contexts. In particular, cardiovascular disease, a major cause of death worldwide, represents a good substrate for the development of innovative methods to tackle this disease.

In addition, the use of nanomaterials can also comply with the requirements underlying the 3Rs rule (Replacement, Reduction and Refinement), which the scientific community is very sensitive to, when designing research involving animal models. Nanoparticles serve as crucial elements for the bio-fabrication of non-animal models.

We invite contributors to submit original research papers or reviews that focus on the recent advances in the field of disease study and treatment design based on nanoparticles, with a particular focus on the cardiovascular system.

Dr. Francesca Pagano
Dr. Francesca Petronella
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • cardiovascular models
  • nanoparticles
  • nanoparticle functionalization
  • non-animal models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3779 KiB  
Article
Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice
by Wioletta Kośnik, Hanna Sikorska, Adam Kiciak and Tomasz Ciach
Int. J. Mol. Sci. 2024, 25(1), 645; https://doi.org/10.3390/ijms25010645 - 4 Jan 2024
Cited by 1 | Viewed by 1061
Abstract
Epirubicin hydrochloride (EPI) is an anticancer drug widely used in the treatment of many solid tumors, including ovarian cancer. Because of its anatomical location, ovarian cancer shows symptoms when it is already in an advanced stage and is thus more difficult to treat. [...] Read more.
Epirubicin hydrochloride (EPI) is an anticancer drug widely used in the treatment of many solid tumors, including ovarian cancer. Because of its anatomical location, ovarian cancer shows symptoms when it is already in an advanced stage and is thus more difficult to treat. Epirubicin hydrochloride kills cancer cells effectively, but its dose escalation is limited by its severe toxicity. By encapsulating epirubicin in dextran-based nanoparticles (POLEPI), we expected to deliver higher and thus clinically more effective doses directly to tumors, where epirubicin would be released and retained longer in the tumor. The antitumor activity of POLEPI compared to EPI was first tested ex vivo in a series of ovarian cancer patient-derived tumor xenografts (PDX). The most promising PDX was then implanted orthotopically into immunocompromised mice, and tumor growth was monitored via magnetic resonance imaging (MRI). Although we succeeded in suppressing the growth of ovarian cancer derived from a patient, in a mouse model by 70% compared to 40% via EPI in 5 days after only one injection, we could not eliminate serious side effects, and the study was terminated prematurely for humane reasons. Full article
Show Figures

Figure 1

Back to TopTop